MARKET

ARDX

ARDX

Ardelyx
NASDAQ
3.780
+0.070
+1.89%
After Hours: 3.760 -0.02 -0.53% 19:30 09/04 EDT
OPEN
3.680
PREV CLOSE
3.710
HIGH
3.780
LOW
3.680
VOLUME
2.98M
TURNOVER
--
52 WEEK HIGH
8.40
52 WEEK LOW
3.680
MARKET CAP
941.93M
P/E (TTM)
-16.7183
1D
5D
1M
3M
1Y
5Y
1D
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
Seeking Alpha · 6d ago
Weekly Report: what happened at ARDX last week (0824-0828)?
Weekly Report · 08/31 09:13
Ardelyx Executives Make Major Moves in Coordinated Insider Sell-Off
TipRanks · 08/26 02:04
Weekly Report: what happened at ARDX last week (0817-0821)?
Weekly Report · 08/24 09:13
Ardelyx Advances Pediatric IBS-C Program With Completed Tenapanor Dose-Ranging Study
TipRanks · 08/19 16:30
Ardelyx Price Target Maintained With a $9.00/Share by Wedbush
Dow Jones · 08/19 12:58
Wedbush Reiterates Outperform on Ardelyx, Maintains $9 Price Target
Benzinga · 08/19 12:48
Ardelyx Price Target Maintained With a $9.00/Share by Wedbush
Dow Jones · 08/18 12:40
More
About ARDX
Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas.

Webull offers Ardelyx Inc stock information, including NASDAQ: ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.